Advertisement

Picture Demy-Colton BioFuture 2021 NYC C Virtual Option 650x80px
Organisation › Details

Merus N.V. (Nasdaq: MRUS)

Merus is a Dutch biotechnology company developing cancer therapeutics based on human bispecific antibodies. Merus’ bispecific antibodies have the robust and proven full-length IgG format, they are manufactured using industry standard processes and have predictable in vivo behavior such as long half-life and low immunogenicity. Merus has two lead programs in development, MCLA-128 for the treatment of HER2 expressing solid tumors, and MCLA-117 for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company is also developing a broad pipeline of preclinical programs in immuno-oncology using its unique technology platforms. *

 

Period Start 2016-05-18 renamed
  Group Merus (Group)
  Predecessor Merus B.V.
Products Industry Biclonics® antibody
  Industry 2 MeMo™ humanized mouse antibody platform
Persons Person Logtenberg, Ton (Merus BV 200601 CEO)
  Person 2 Crowley, John (Merus 201611– CFO based in US before Charles River + Vertex + Sunovian)
     
Region Region Utrecht
  Country Netherlands
  Street 8 Padualaan
  City 3584 CH Utrecht
  Tel +31-30-253-8800
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: 
     
   
Record changed: 2021-04-01

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Merus (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top